Bispecific antibody https://www.bioworld.com/rss en-us Galapagos enters new era as Lakefront after reshaping Gilead alliance http://www.bioworld.com/articles/729964 Tue, 31 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729964-galapagos-enters-new-era-as-lakefront-after-reshaping-gilead-alliance Handshake icon engraved on metal hexagonal background HXN-1023 drives robust anti-inflammatory responses in atopic dermatitis models http://www.bioworld.com/articles/730040 Tue, 31 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/730040-hxn-1023-drives-robust-anti-inflammatory-responses-in-atopic-dermatitis-models Skin, tissue layer illustration NAV-242 bispecific antibody supports quarterly dosing in HS http://www.bioworld.com/articles/730036 Tue, 31 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/730036-nav-242-bispecific-antibody-supports-quarterly-dosing-in-hs More than two to tango: multispecifics at ESMO TAT http://www.bioworld.com/articles/729995 Fri, 27 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729995-more-than-two-to-tango-multispecifics-at-esmo-tat Antibodies artwork Multibody TEV‘325 achieves preclinical milestone http://www.bioworld.com/articles/729930 Thu, 26 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729930-multibody-tev325-achieves-preclinical-milestone Illustration of a road with three destination markers Excalipoint closes $68.7M seed round for cancer T-cell engagers http://www.bioworld.com/articles/729898 Tue, 24 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729898-excalipoint-closes-687m-seed-round-for-cancer-t-cell-engagers Blue-gray dollar sign Imbiologics crosses $1B market cap with Kosdaq debut http://www.bioworld.com/articles/729897 Tue, 24 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729897-imbiologics-crosses-1b-market-cap-with-kosdaq-debut Ha-Gyong-sik, CEO, Imbiologics Imbiologics CEO Ha-Gyong-sik at the company's IPO ceremony. Simcere’s PD-L1/IL-15 bispecific sees early edge in bladder cancer http://www.bioworld.com/articles/729895 Tue, 24 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729895-simceres-pd-l1-il-15-bispecific-sees-early-edge-in-bladder-cancer Bladder cancer illustration Laigo extends seed round as targeted protein degradation field gathers pace http://www.bioworld.com/articles/729812 Mon, 23 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729812-laigo-extends-seed-round-as-targeted-protein-degradation-field-gathers-pace White Euro symbol on blue background Imbiologics crosses $1B market cap with Kosdaq debut http://www.bioworld.com/articles/729763 Fri, 20 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729763-imbiologics-crosses-1b-market-cap-with-kosdaq-debut Ha-Gyong-sik, CEO, Imbiologics Imbiologics CEO Ha-Gyong-sik at the company's IPO ceremony. Excalipoint closes $68.7M seed round for cancer T-cell engagers http://www.bioworld.com/articles/729788 Thu, 19 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729788-excalipoint-closes-687m-seed-round-for-cancer-t-cell-engagers Blue-gray dollar sign Simcere’s PD-L1/IL-15 bispecific sees early edge in bladder cancer http://www.bioworld.com/articles/729564 Wed, 18 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729564-simceres-pd-l1-il-15-bispecific-sees-early-edge-in-bladder-cancer Bladder cancer illustration Excalipoint closes $68.7M seed round for cancer T-cell engagers http://www.bioworld.com/articles/729560 Wed, 18 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729560-excalipoint-closes-687m-seed-round-for-cancer-t-cell-engagers Blue-gray dollar sign Kanaph’s $27M IPO to aid multi-modality cancer, immune portfolio http://www.bioworld.com/articles/729715 Tue, 17 Mar 2026 11:00:00 -0400 https://www.bioworld.com/articles/729715-kanaphs-27m-ipo-to-aid-multi-modality-cancer-immune-portfolio Lee Byoung-chul, CEO, Kanaph Kanaph CEO Lee Byoung-chul at the company's IPO ceremony. Kanaph, Imbiologics to kick off 2026 Korea biotech, med-tech IPOs http://www.bioworld.com/articles/729714 Tue, 17 Mar 2026 11:00:00 -0400 https://www.bioworld.com/articles/729714-kanaph-imbiologics-to-kick-off-2026-korea-biotech-med-tech-ipos Ha Gyong sik giving a presentation Ha Gyong-sik, CEO, Imbiologics Mestag raises $40M to take fibroblast program into phase I cancer trial http://www.bioworld.com/articles/729707 Tue, 17 Mar 2026 08:00:00 -0400 https://www.bioworld.com/articles/729707-mestag-raises-40m-to-take-fibroblast-program-into-phase-i-cancer-trial Fibroblast illustration Kanaph’s $27M IPO to aid multi-modality cancer, immune portfolio http://www.bioworld.com/articles/729533 Mon, 16 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729533-kanaphs-27m-ipo-to-aid-multi-modality-cancer-immune-portfolio Lee Byoung-chul, CEO, Kanaph Kanaph CEO Lee Byoung-chul at the company's IPO ceremony. JNJ-79032421, a membrane-restricted MSLN-targeting T-cell-engaging bispecific antibody http://www.bioworld.com/articles/729647 Mon, 16 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729647-jnj-79032421-a-membrane-restricted-msln-targeting-t-cell-engaging-bispecific-antibody 3D illustration of T cells fighting cancer Kanaph, Imbiologics to kick off 2026 Korea biotech, med-tech IPOs http://www.bioworld.com/articles/729495 Fri, 13 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729495-kanaph-imbiologics-to-kick-off-2026-korea-biotech-med-tech-ipos Ha Gyong sik giving a presentation Ha Gyong-sik, CEO, Imbiologics HX-16108 holds promise for treating inflammatory skin diseases http://www.bioworld.com/articles/729592 Wed, 11 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729592-hx-16108-holds-promise-for-treating-inflammatory-skin-diseases Skin irritation on hands China’s NMPA clears HBM-7575 to enter clinic in atopic dermatitis http://www.bioworld.com/articles/729413 Mon, 09 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729413-chinas-nmpa-clears-hbm-7575-to-enter-clinic-in-atopic-dermatitis Green and red bispecific antibodies CD19xγδ bispecific antibody selectively activates Vγ9Vδ2 T cells for the treatment of B-ALL http://www.bioworld.com/articles/729395 Fri, 06 Mar 2026 08:00:00 -0500 https://www.bioworld.com/articles/729395-cd19x-bispecific-antibody-selectively-activates-v9v2-t-cells-for-the-treatment-of-b-all 3d rendering of bispecific antibodies Systimmune’s iza-bren hits phase III breast cancer goals in China http://www.bioworld.com/articles/729321 Tue, 03 Mar 2026 12:00:00 -0500 https://www.bioworld.com/articles/729321-systimmunes-iza-bren-hits-phase-iii-breast-cancer-goals-in-china Cancer tumor in breast illustration Systimmune’s iza-bren hits phase III breast cancer goals in China http://www.bioworld.com/articles/729258 Fri, 27 Feb 2026 12:00:00 -0500 https://www.bioworld.com/articles/729258-systimmunes-iza-bren-hits-phase-iii-breast-cancer-goals-in-china Cancer tumor in breast illustration Ailux characterizes ALX-001 for IMIDs http://www.bioworld.com/articles/729018 Tue, 24 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/729018-ailux-characterizes-alx-001-for-imids Illustration of macrophage releasing cytokines First-in-class LTβR x EDB bispecific antibody overcomes checkpoint resistance http://www.bioworld.com/articles/728972 Mon, 23 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/728972-first-in-class-ltr-x-edb-bispecific-antibody-overcomes-checkpoint-resistance Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow AI meets antibody design: Galux draws $29M series B for drug R&D http://www.bioworld.com/articles/728806 Tue, 10 Feb 2026 11:00:00 -0500 https://www.bioworld.com/articles/728806-ai-meets-antibody-design-galux-draws-29m-series-b-for-drug-r-and-d Park Tae-yong, vice president and cofounder, Galux Park Tae-yong, vice president and cofounder, Galux Inc. AI meets antibody design: Galux draws $29M series B for drug R&D http://www.bioworld.com/articles/728800 Tue, 10 Feb 2026 09:00:00 -0500 https://www.bioworld.com/articles/728800-ai-meets-antibody-design-galux-draws-29m-series-b-for-drug-r-and-d Park Tae-yong, vice president and cofounder, Galux Park Tae-yong, vice president and cofounder, Galux Inc. Almirall files CTA for bispecific antibody for atopic dermatitis http://www.bioworld.com/articles/728769 Tue, 10 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/728769-almirall-files-cta-for-bispecific-antibody-for-atopic-dermatitis 3D illustration of the cross-section of skin layers with atopic dermatitis AI meets antibody design: Galux draws $29M series B for drug R&D http://www.bioworld.com/articles/728701 Mon, 09 Feb 2026 12:00:00 -0500 https://www.bioworld.com/articles/728701-ai-meets-antibody-design-galux-draws-29m-series-b-for-drug-r-and-d Park Tae-yong, vice president and cofounder, Galux Park Tae-yong, vice president and cofounder, Galux Inc.